Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448678 | 1.00 | IDO1 (0.41) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL16686216 | 0.79 | IDO1 (0.43) | IDO1AGXTTRPV6CA1CA2 | |
| Methyl Alcohol SCHEMBL8601404 | 0.77 | CA1 (0.42) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL3049370 | 0.77 | NAAA (0.43) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL16685703 | 0.77 | IDO1 (0.41) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL15536619 | 0.76 | IDO1 (0.47) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL26986104 | 0.75 | CA1 (0.43) | IDO1AGXTTRPV6CA1CA2 | |
| SCHEMBL16685927 | 0.74 | HTT (0.45) | CA1CA2 | |
| SCHEMBL34413 | 0.71 | IDO1 (0.67) | IDO1AGXTCA1CA2APP | |
| SCHEMBL29879670 | 0.70 | NPC1 (0.47) | IDO1AGXTCA1CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |